Ethionamide
Top View
- Public Assessment Report
- ICCB-L Plate (10 Mm / 3.33 Mm) ICCB-L Well Vendor ID Chemical Name
- The Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in Singapore: Are Patients from South-East Asia Eligible?
- Towards Improved Treatment Outcomes for Tuberculosis Meningitis - Rethinking the Regimen
- Validation and Application of a Novel Target-Based Whole-Cell Screen to Identify Antifungal Compounds
- Pharmacokinetics and Dosing Rationale of Para
- Chapter 6 Treatment of Tuberculosis Disease
- E.Johnson Supplementary
- Section V. Treatment of Drug-Resistant Tuberculosis
- An Activist's Guide to Tuberculosis Drugs 2016 Update
- Anti-Leprosy Drugs: Modes of Action and Mechanisms of Resistance in Mycobacterium Leprae
- Ethionamide (Eto)/Protionamide (Pto) DRUG CLASS: CARBOTHIONAMIDES GROUP, DERIVATIVES of ISONICOTINIC ACID
- Pharmaceutical Appendix to the Harmonized Tariff Schedule
- Critically Important Antimicrobials for Human Medicine, 6Th Revision
- High Ethionamide Resistance in Mycobacterium Tuberculosis Strains Isolated in Kenya
- Multi-Omics Technologies Applied to Tuberculosis Drug Discovery
- An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy (2006)
- Pharmaceuticals Appendix